| 参考文献: |
1. Liddle J, et al. The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. 2. Thornton, S., et al., (2015). Treatment of spontaneous preterm labour with retosiban: a phase 2 proof-of-concept study. British journal of clinical pharmacology, 80(4), 740-749. 3. Borthwick, A. D., et al., (2011). The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. Medicinal research reviews, 31(4), 576–604. 4. McCafferty, G. P., et al., (2007). Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat. American journal of physiology. Regulatory, integrative and comparative physiology, 293(1), R299–R305. 5. Moraitis, A. A., et al., (2015). The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch. Endocrinology, 156(10), 3511–3516. |